BIEL PPS EXPLOSION COMING — THE FULL SETUP
Wearable‑Health Boom (Apple Watch, Oura Ring)
+ Verified 400% PPS Surge Momentum
+ Electrome AI Platform
+ VC Validation (Capital Factory)
+ Haleon Consumer Health Vertical
+ Veterinary AI Expansion
A PERFECT POWDER KEG
Supply squeeze. Multi‑industry AI demand. OEM revenue explosion.
The setup is textbook.
LEVEL 2: THE SPARK
Only 18M left @ .0004 — versus nearly 300M @ .0002 months ago.
The wall is gone. The fuse is lit.
400% RUN = HISTORIC
BIEL’s move from .0001 → .0005 places it in the top 0.1% of all traded securities.
This triggers:
• Algorithmic flags
• Momentum scanners
• Quant‑fund attention
• Viral visibility
ELECTROME = THE AI ENGINE
Electrome is an AI‑native therapeutics platform, and every node runs on BIEL PEMF hardware.
This is the “Intel Inside” moment for bioelectric medicine.
VC VALIDATION (CAPITAL FACTORY)
Capital Factory backing = institutional credibility.
They vet high‑growth startups — and Electrome depends entirely on BIEL hardware.
BIEL becomes indirectly VC‑validated.
OEM REVENUE ENGINE #1 — HUMAN HEALTH
PAINKILLER™ + AI verticals = compounding hardware demand.
Forecasts:
• 50k–150k units → $0.75M–$2.25M
• Multi‑vertical expansion → $4M–$7M
• 1–3% chronic pain penetration → $7.5M–$22M+
OEM REVENUE ENGINE #2 — VETERINARY AI
$120B market. Lower barriers. Exploding demand.
Forecast:
• Elite performance animals → $500K–$1.2M
• 5,000+ specialty clinics → $3M–$7.5M
• Global pet wearables → $12M–$25M+
OEM REVENUE ENGINE #3 — HALEON
Global distribution + drug‑free wellness demand.
Forecast:
• Pilots → $2M–$5M
• Global rollout → $15M–$35M
• Mass‑market wearables → $50M–$100M+
THE UNIFIED ECOSYSTEM
Electrome AI = the brain
BIEL PEMF = the engine
Every user = recurring hardware node
PUBLICITY CATALYST
A move to .003 makes BIEL a national story — a 3,000% gain from .0001.
This generates millions in free media across AI, bioelectric medicine, consumer health, and veterinary tech.
THE BIEL QUANTUM LEAP
If BIEL delivers $2.5M net profit, it could command a $2.5B market cap → $0.10 PPS.
High‑narrative disruptors routinely trade at P/E > 1,000.
PROFITABILITY IS WITHIN REACH
BIEL has already shown profit:
• Q3 2021 profit: $22,381
• Revenue: $414,700
Ultra‑lean model → profitability is not theoretical.
PPS PROJECTIONS
• .001 — Technical breakout
• .003 — Momentum‑driven media cycle
• .01 — Cash‑flow positive
• .10 — Profit‑driven valuation
• 1.00 — Post‑debt, buyback era
TAX ADVANTAGE
BIEL holds a $41M tax‑loss carryforward — first $40M in profits are tax‑free.
WEARABLE‑HEALTH MACRO WAVE
Oura, Apple, WHOOP, Samsung, Garmin — all racing toward continuous sensing + personalized interventions.
ActiPatch is the only FDA‑cleared PEMF engine ready to plug into this boom.
Revenue Projections for BIEL Under an Oura-Integrated Scenario
These are scenario models, not predictions — but they illustrate the scale of impact if Oura adopted BIEL hardware as the therapeutic layer of its ecosystem.
Assumptions Used for Modeling
BIEL acts as OEM manufacturer for Electrome’s therapeutic modules
Oura integrates or co-bundles PEMF patches/devices
BIEL revenue = hardware unit sales + recurring replacement patches
Conservative wholesale pricing: $12–$18 per unit
Enterprise adoption grows faster than consumer adoption
Scenario 1: Conservative (0.5% Oura User Penetration)
Oura user base: about 2.5M
Adoption: 0.5% (12,500 users)
Avg. annual PEMF consumption per user: 12–18 units
Estimated BIEL Revenue:
$1.8M – $3.4M annually
Scenario 2: Moderate (2% Oura User Penetration + Enterprise Pilot Deals)
Consumer adoption: 50,000 users
Enterprise pilots: 10–20 employers (5,000–10,000 employees)
Annual PEMF consumption: 12–18 units
Estimated BIEL Revenue:
$10M – $18M annually
Scenario 3: Aggressive (5% Consumer + Enterprise + Defense Integration)
Consumer adoption: 125,000 users
Enterprise/Defense: 50,000–100,000 employees
Annual PEMF consumption: 12–18 units
Estimated BIEL Revenue:
$22M – $40M annually
This scenario aligns with the scale of Oura’s existing enterprise footprint.
The Takeaway
Oura’s $11B valuation proves that the market rewards continuous health ecosystems — but the next frontier is therapeutic wearables, not just tracking wearables.
SUMMARY
The wearable‑health boom is the macro wave.
BIEL + Electrome is the microcap positioned directly in its path.
Wearable‑Health Boom (Apple Watch, Oura Ring)
+ Verified 400% PPS Surge Momentum
+ Electrome AI Platform
+ VC Validation (Capital Factory)
+ Haleon Consumer Health Vertical
+ Veterinary AI Expansion
A PERFECT POWDER KEG
Supply squeeze. Multi‑industry AI demand. OEM revenue explosion.
The setup is textbook.
LEVEL 2: THE SPARK
Only 18M left @ .0004 — versus nearly 300M @ .0002 months ago.
The wall is gone. The fuse is lit.
400% RUN = HISTORIC
BIEL’s move from .0001 → .0005 places it in the top 0.1% of all traded securities.
This triggers:
• Algorithmic flags
• Momentum scanners
• Quant‑fund attention
• Viral visibility
ELECTROME = THE AI ENGINE
Electrome is an AI‑native therapeutics platform, and every node runs on BIEL PEMF hardware.
This is the “Intel Inside” moment for bioelectric medicine.
VC VALIDATION (CAPITAL FACTORY)
Capital Factory backing = institutional credibility.
They vet high‑growth startups — and Electrome depends entirely on BIEL hardware.
BIEL becomes indirectly VC‑validated.
OEM REVENUE ENGINE #1 — HUMAN HEALTH
PAINKILLER™ + AI verticals = compounding hardware demand.
Forecasts:
• 50k–150k units → $0.75M–$2.25M
• Multi‑vertical expansion → $4M–$7M
• 1–3% chronic pain penetration → $7.5M–$22M+
OEM REVENUE ENGINE #2 — VETERINARY AI
$120B market. Lower barriers. Exploding demand.
Forecast:
• Elite performance animals → $500K–$1.2M
• 5,000+ specialty clinics → $3M–$7.5M
• Global pet wearables → $12M–$25M+
OEM REVENUE ENGINE #3 — HALEON
Global distribution + drug‑free wellness demand.
Forecast:
• Pilots → $2M–$5M
• Global rollout → $15M–$35M
• Mass‑market wearables → $50M–$100M+
THE UNIFIED ECOSYSTEM
Electrome AI = the brain
BIEL PEMF = the engine
Every user = recurring hardware node
PUBLICITY CATALYST
A move to .003 makes BIEL a national story — a 3,000% gain from .0001.
This generates millions in free media across AI, bioelectric medicine, consumer health, and veterinary tech.
THE BIEL QUANTUM LEAP
If BIEL delivers $2.5M net profit, it could command a $2.5B market cap → $0.10 PPS.
High‑narrative disruptors routinely trade at P/E > 1,000.
PROFITABILITY IS WITHIN REACH
BIEL has already shown profit:
• Q3 2021 profit: $22,381
• Revenue: $414,700
Ultra‑lean model → profitability is not theoretical.
PPS PROJECTIONS
• .001 — Technical breakout
• .003 — Momentum‑driven media cycle
• .01 — Cash‑flow positive
• .10 — Profit‑driven valuation
• 1.00 — Post‑debt, buyback era
TAX ADVANTAGE
BIEL holds a $41M tax‑loss carryforward — first $40M in profits are tax‑free.
WEARABLE‑HEALTH MACRO WAVE
Oura, Apple, WHOOP, Samsung, Garmin — all racing toward continuous sensing + personalized interventions.
ActiPatch is the only FDA‑cleared PEMF engine ready to plug into this boom.
Revenue Projections for BIEL Under an Oura-Integrated Scenario
These are scenario models, not predictions — but they illustrate the scale of impact if Oura adopted BIEL hardware as the therapeutic layer of its ecosystem.
Assumptions Used for Modeling
BIEL acts as OEM manufacturer for Electrome’s therapeutic modules
Oura integrates or co-bundles PEMF patches/devices
BIEL revenue = hardware unit sales + recurring replacement patches
Conservative wholesale pricing: $12–$18 per unit
Enterprise adoption grows faster than consumer adoption
Scenario 1: Conservative (0.5% Oura User Penetration)
Oura user base: about 2.5M
Adoption: 0.5% (12,500 users)
Avg. annual PEMF consumption per user: 12–18 units
Estimated BIEL Revenue:
$1.8M – $3.4M annually
Scenario 2: Moderate (2% Oura User Penetration + Enterprise Pilot Deals)
Consumer adoption: 50,000 users
Enterprise pilots: 10–20 employers (5,000–10,000 employees)
Annual PEMF consumption: 12–18 units
Estimated BIEL Revenue:
$10M – $18M annually
Scenario 3: Aggressive (5% Consumer + Enterprise + Defense Integration)
Consumer adoption: 125,000 users
Enterprise/Defense: 50,000–100,000 employees
Annual PEMF consumption: 12–18 units
Estimated BIEL Revenue:
$22M – $40M annually
This scenario aligns with the scale of Oura’s existing enterprise footprint.
The Takeaway
Oura’s $11B valuation proves that the market rewards continuous health ecosystems — but the next frontier is therapeutic wearables, not just tracking wearables.
SUMMARY
The wearable‑health boom is the macro wave.
BIEL + Electrome is the microcap positioned directly in its path.
1
